MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $81.43 Consensus Price Target from Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have received an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $84.29.

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $62.00 to $82.00 in a research report on Friday. Wedbush reissued an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th.

MoonLake Immunotherapeutics Stock Up 5.6 %

NASDAQ:MLTX opened at $43.81 on Friday. The company has a 50-day moving average price of $51.63 and a 200-day moving average price of $49.01. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period last year, the firm posted ($0.18) EPS. Research analysts forecast that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of MoonLake Immunotherapeutics by 35.8% during the third quarter. FMR LLC now owns 4,950,224 shares of the company’s stock valued at $249,590,000 after buying an additional 1,306,215 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in MoonLake Immunotherapeutics by 7.4% during the 2nd quarter. Avoro Capital Advisors LLC now owns 2,770,000 shares of the company’s stock valued at $121,797,000 after purchasing an additional 190,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in MoonLake Immunotherapeutics by 4.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,167,358 shares of the company’s stock valued at $58,858,000 after purchasing an additional 49,733 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of MoonLake Immunotherapeutics by 2.6% in the 2nd quarter. Federated Hermes Inc. now owns 1,128,428 shares of the company’s stock worth $49,617,000 after purchasing an additional 28,672 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of MoonLake Immunotherapeutics by 115.0% in the second quarter. Marshall Wace LLP now owns 1,098,630 shares of the company’s stock worth $48,307,000 after purchasing an additional 587,684 shares during the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.